The drug treats fast-growing, deadly brain cancers with no effective treatment.
Technology Ventures News
Seeking new ways to help patients manage lupus
In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
Adakveo significantly reduces pain crises in sickle cell patients.
The funding will help bring Progentec’s tool for identifying lupus flare ups and a biomarker-based disease-activity index closer to commercialization.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.